Sustainability and predictability of the markets are key to make the most of the #biosimilar opportunity, to unlock better: 👤 patient access 👩‍⚕️ physician prescription choice 💰 management of healthcare budgets 🚚 security of supply #BIOS22

Efficient procurement policies for #biosimilar medicines should feature: 🪟 free, fair and open competition ⚖️ balanced decision making 📑 tender criteria beyond price 🏆 multiple awardees ⚙️ transparence in planning and implementation 📣 communication #BIOS22 Medicines for Europe

The benefits deriving from purchasing best-value biologics can and should be transformed into tangible improvements for patients and the healthcare community. #BIOS22 Medicines for Europe

Regulatory science advances are shared worldwide but local regulations on #biosimilar medicines naturally evolve at varying paces, with regulators focusing on different aspects of the biosimilar framework at different times. #BIOS22 Medicines for Europe

Come misuriamo il valore aggiunto di un farmaco? Con quali dati determiniamo i benefici di una terapia? Gli esperti dell’evento Il Valore Aggiunto alla Salute di Egualia discutono il futuro delle #ValueAddedMeds ed il ruolo della #RealWorldEvidence nella loro valutazione

Perché continuare ad esplorare diversi usi terapeutici di un farmaco anche quando lo utilizziamo già da molti anni? In questo breve video girato all'evento Il Valore Aggiunto alla Salute di Egualia provo a rispondere a questa domanda. youtu.be/LXFKNwIj7Eo HealthDesk

⚕️ Le #ValueAddedMeds - o VAM - sono farmaci innovativi che vengono sviluppati a partire da molecole già in uso nella pratica clinica. Insieme ad alcuni tra i maggiori esperti in Italia ne ho parlato al recente evento di Egualia ⬇️ youtu.be/-fc8tE8jL08

We need a #OneHealth approach to fight #AMR #AntimicrobialResistance Health First Europe 🇪🇺 European AMR Patient Group 🇪🇺

Off-patent #medicines unlock better access to treatment when the right policies are in place #AccessForAll Medicines for Europe

To ensure sustainable supplies of #medicines we must consider the long-term impact of strategies and policy measures EU2022_CZ Medicines for Europe @CZECHIAinEU #AccessForAll

Four Caians swapped rowing on the Cam for the Grand Canal in September. Heqing Huang (Sociology PhD 2017), Marta Baldrighi (Medicine PhD 2015), Jilles Fermont (Medicine PhD 2016), and Xiao Zheng (NatSci 2014) rowed in the Regata Storica di Venezia. 📰: cai.cam.ac.uk/news/caians-ro…

Continuous innovation on existing #medicines can respond to some of the most pressing #healthcare challenges of our times #VAM22 Medicines for Europe

Drug #repurposing is a clever innovation strategy identifying new uses for well-established medicines, yet we have not fully realised its potential for European patients. There are different ways to change this and a clear role for the pharmaceutical industry going ahead #VAM22

The benefits of #ValueAddedMeds go beyond health gains that can be captured in clinical trials. #RealWorldEvidence gives insights into many of the improvements that these medicines can deliver and highlights how they can reshape #healthcare to make it more patient-centric #VAM22

Continuous innovation requires a specific framework and ecosystem to best deliver improved and optimised #medicines for European patients. The revision of the #EUPharmaLegislation offers an opportunity to lay the foundation of this new system. #VAM22

💊 #DrugRepurposing opens a new window of opportunity for patients by reducing the barriers needed to find cost effective therapeutics.   📢 #VAMWeek is continuing this discussion and today’s topic is #MedsRepurposing. 🤝 Join them in the debate and follow Medicines for Europe.

Lo sapevamo già in fondo, ma i dati sono brutali. Su 100 ricercatori ERC accolti nelle università italiane, 91 sono Italiani. Su 100 italiani vincitori di ERC, 55 lo svolgono all'estero. Tanti italiani partono, ma soprattutto, nessuno arriva. Bisogna fare davvero qualcosa.

#Cover: PLK1 regulates NLRP3 inflammasome activation by controlling microtubule organization: buff.ly/3MmUEgj Xuan Li_Lab Marta Baldrighi Xiaohui Zhao Emily 🏳️‍🌈👩‍🔬 Murray Clarke Lab Guillermo de Cárcer @m_malumbres Ziad Mallat #CellBiology #Immunology

PoV: your main PhD paper is finally published but the Uni's comms office decides that your cell biology and immunology research is best represented by a *big ugly foot* 👣 Still super proud, though. Great team effort Xuan Li_Lab cam.ac.uk/research/news/…

Yesterday I attended the Basel Epidemiology Seminar and I picked up my iPad again to summarise a talk. My drawing felt a bit rusty but it was fun to do this again after such a long time! 🙂